Clinical Trials for Bladder Cancer
CA209-901
A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer. Click here to learn more.
DZB-CS-201
Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02). Click here to learn more.
NORSE
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer. Click here to learn more.
THOR
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations. Click here to learn more.
TTX-030-002
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. Click here to learn more.
